Remove tag small-molecule
article thumbnail

Takeda Pairs Up With BridGene to Solve "Undruggable" Neurodegenerative Diseases

BioSpace

The companies will harness BridGene’s IMTAC (Isobaric Mass Tagged Affinity Characterization) Chemoproteomics platform to identify targets and small molecule drug candidates.

Drugs 71
article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Rather than investing more in R&D, most pharma companies feel its more cost-effective to buy small biotech companies developing unique molecules that can find a market niche.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Immunocore gets EU nod for TCR cancer therapy Kimmtrak

pharmaphorum

The therapy is a bispecific T cell engager (BiTE) molecule, consisting of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes. It’s the first treatment for mUM in the EU, as well as the first BiTE drug to treat a solid tumour. ” Image by Pexels from Pixabay .

Sales 52
article thumbnail

Almirall and IRB Barcelona team up to tackle skin disease

pharmaphorum

However, states the company, many of these potentially therapeutically relevant proteins are “not amenable to conventional small-molecule inhibitors, as they lack defined ligand-binding pockets”. Researchers at Almirall have identified several proteins whose abnormal function is associated with inflammatory immune skin diseases.

article thumbnail

Sponsored content: Why choose Bethyl antibodies for your R&D

Drug Discovery World

Pillar 5: Protein OE/Epitope Tags. Small molecules . This pillar requires that antibody-independent and antibody-dependent assays produce results that are correlative. Pillar 4: Biological Characteristics. This pillar takes advantage of the unique biology associated with some protein targets. Our areas of expertise.

article thumbnail

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. Across the world, to varying degrees, the regulations were written in an era of small molecules and biologics. AZ: How can regulators ensure that they nurture future innovations in the field?

article thumbnail

Targeting a human protein may stop Ebola virus in its tracks

The Pharma Data

This special enzyme, once fused to Ebola virus polymerase, enables the polymerase to add a molecular tag to any other protein it interacts with. By fishing out proteins that contain this unique tag, researchers could map out the complex series of Ebola virus polymerase-host protein interactions.

Protein 52